Table 2 Release of AA from HCT-15 cells by NSAIDs and several cancer preventive agents. Such experiments were performed several times with similar results. The experimental conditions are similar to those given in Table 1.
Drug tested | Concentration | AA Release *, †|
|---|---|---|
MEM/BSA (control) | 0 | 3.2 ± 0.09 (5) |
NaCl | 10 mM | 3.3 ± 0.12 (3) |
A) NSAIDs ** | ||
Acetylsalicylic acid | 10 mM | 3.6 ± 0.13 (5) |
Diflunisac | 460 μM | 6.7 ± 0.28 (3) |
Naproxine | 3 mM | 4.1 ± 0.29 (3) |
Na salicylate | 10 mM | 5.6 ± 0.18 (5) |
NS398 | 52 μM | 4.7 ± 0.35 (5) |
Piroxicam | 10 mM | 4.2 ± 0.33 (5) |
Rofecoxib, (Vioxx®) *** | 100 μM | 4.2 ± 0.41 (3) |
Valdecoxib, (Bextra®)*** | 178 μM | 6.2 ± 0.44 (3) |
B) Drugs that are not NSAIDs – several are cancer preventative. | ||
Acetaminophen | 10 mM | 4.0 ± 0.11 (5) |
(-)-Epigallocatechin gallate | 224 μM | 4.3 ± 0.19 (3) |
17 β-Estradiol | 100 μM | 4.5 ± 0.48 (3) |
GW-7845 | 50 μM | 9.5 ± 0.39 (3) |
Raloxifene | 50 μM | 10.9 ± 0.47 (4) |
Raloxifene | 100 μM | 13.3 ± 0.64 (3) |
9-cis-retinoic acid | 83 μM | 7.5 ± 0.36 (3) |
Resveritrol | 100 μM | 5.0 ± 0.29 (3) |